Navigation Links
Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma

LACHEN, Switzerland, May 1 /PRNewswire/ --

- Company Working With Authorities to Ensure Adequate Supply of Virally Inactivated Plasma Derivatives

The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based global biopharmaceutical company, Octapharma.

But it has reiterated the safety of its plasma derivatives and is working closely with health authorities and plasma suppliers to maintain the safety profile and continuous supply of its lifesaving products.

The threat to blood supplies arises as blood transfusion authorities across the globe remind blood donors to stay away if they have 'flu-like symptoms. In Germany, the Paul Ehrlich Institute, which tests blood products on behalf of the German federal health ministry, has recommended against using blood donated by people who have travelled to countries affected by the swine influenza outbreak or who have been in close contact with people who have 'flu-like symptoms or were in 'flu-affected countries in the previous 14 days.

Octapharma makes plasma derivatives used in a range of medical emergencies. The new swine H1N1 virus, with its epicentre in Mexico, does not endanger the safety of Octapharma's products. Octaplas(R), is a virally inactivated pooled plasma, which can be used in emergency situations whenever plasma transfusion is required.

Currently, Octapharma has sufficient supplies of Octaplas(R) to satisfy usual client demand. Production can be increased by up to 30 percent if demand increases. Octapharma already provides 100 per cent of plasma needs with Octaplas(R) for transfusion in Norway, Finland and Portugal.

During the manufacture of Octaplas(R), the product undergoes a solvent-detergent treatment that destroys the lipid enveloped membrane of a virus, making it inactive and unable to infect.

All influenza viruses are lipid enveloped viruses and not very resistant to inactivation. The H1N1 virus is completely inactivated by the procedures used in the manufacture of Octaplas(R) and other blood-derived biopharmaceutical products.

Notes for editors


The Octapharma Group is an independent, Swiss-based biopharmaceutical company operating worldwide. Octapharma's core business is the development, production, and sale of high-quality human proteins for the treatment of life-threatening diseases. The Group has more than 3,000 employees in 28 countries, and owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden, and Mexico, respectively.

Octapharma's company mission is to provide safe and effective biopharmaceutical products derived from human blood plasma to patients in need of lifesaving therapy.

For more information about the company please visit tapharma_news_021609.html

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

SOURCE Octapharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
2. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
3. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
8. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):